In addition, the fact that PP2A activation status determines 5-FU response of CRC cells [34] prompted us to analyze the clinical role of the miR-19b/PPP2R5E axis in LARC due to 5-FU-based treatment is the standard neoadjuvant therapy in this disease. This evidence concerns the gene PTPA and colorectal carcinoma.